Physician profile
Digna Cespedes-Cloud
NPI 1457826133
$7,518.47
in general payments reported to CMS, 2019-2025
37 companies · $2,452 in 2025
The $2,452 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $420 · 2022: $1,884 · 2023: $1,568 · 2024: $1,194 · 2025: $2,452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,213.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $916.30 | 2021-2025 | |
| Novo Nordisk INC | $608.09 | 2021-2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $530.75 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $513.62 | 2022-2025 | Ajovy |
| Alexion Pharmaceuticals, INC. | $459.67 | 2023-2024 | Ultomiris, Soliris |
| Astrazeneca Pharmaceuticals LP | $457.63 | 2021-2025 | Fasenra |
| Sanofi-Aventis U.S. LLC | $308.71 | 2022-2025 | |
| Alkermes, INC. | $216.78 | 2023-2025 | Lybalvi, Aristada |
| Idorsia Pharmaceuticals US INC | $211.14 | 2023 | Quviviq |
| Biogen, INC. | $192.58 | 2022 | |
| Neurocrine Biosciences, INC. | $178.36 | 2022-2023 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $167.67 | 2021-2023 | |
| Vertex Pharmaceuticals Incorporated | $166.62 | 2025 | |
| Vanda Pharmaceuticals INC. | $159.87 | 2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $143.60 | 2025 | Auvelity |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Digna Cespedes-Cloud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.